Info
Relapsed refractory of treatment and prognosis of multiple myeloma (MM)
- HSCT (if good prior response, no prior HSCT),
- Elo-PD,
- Dara-PD,
- venetoclax (anti-Bcl-2) + dex in t(11;14);
- rarely use Allo-SCT. CAR-T w/ idecabtagene vicleucel (anti-B-cell maturation antigen) after >3 prior Rx: response rates >70% (NEJM 2019;380:1726 & 2021;384:705).